检索结果-南通市图书馆

全国第二次冠心病介入性治疗病例注册登记资料分析

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

中华心血管病杂志 2000年第1期28卷 10-13页

作者： Section of Interventional cardiology, chinese society of cardiology, chinese medical association, et al. (Correspondent: GAO Runlin. Fu Wai Hospital, PUMC & CAMS, Beijing 100037, China) 中华医学会心血管病学分会介入心脏病学组中华心血管病杂志编辑部

目的　分析 1997年和 1998年我国冠心病介入性治疗发展趋势。方法　采用填写统一发放的表格的方法 ,收集 1997、1998两年各医院冠心病介入性治疗病例资料 ,进行回顾性分析。结果共注册经皮冠状动脉腔内成形术 (PTCA)病例总数 872 5例 ,... 详细信息

目的　分析 1997年和 1998年我国冠心病介入性治疗发展趋势。方法　采用填写统一发放的表格的方法 ,收集 1997、1998两年各医院冠心病介入性治疗病例资料 ,进行回顾性分析。结果共注册经皮冠状动脉腔内成形术 (PTCA)病例总数 872 5例 ,来自全国范围内 75所医院 ,总成功数 83 69例 (95 9% )。其中 1997年 3 74 0例 ,成功 3 5 5 3例 (95 0 % ) ;1998年 4 985例 ,成功 4 816例 (96 6% )。共扩张病变 10 2 18处 ,成功 965 0处 ,病变成功率为 94 4 %。急性心肌梗死 (AMI)急诊PTCA 10 4 5例 ,成功10 0 1例 (95 8% )。全组患者发生重要并发症 95 9例 (11 0 % ) ,包括死亡 3 2例 (0 3 7% )。冠状动脉支架置入术 63 2 9例 ,共置入支架 774 8只 ,其中左冠状动脉主干置入支架 86只 (占 1 1% )。置入成功7677只 (99 1% )。发生重要并发症 5 10例 (8 1% ) ,包括死亡 2 5例 (0 4 0 % )。全部患者服用噻氯匹啶 ,其中 13 8例 (1 8% )发生粒细胞减少症。另外 ,注册登记冠状动脉斑块旋磨术 93例 (94支血管 ) ,成功率为 93 6%。结论　 1997年和 1998年我国冠心病介入治疗例数有大幅度增长 ,两年内完成病例数远远超过过去 12年积累病例总数 ,成功率较过去有增加趋势 ,但地区间及医院间发展仍很不平衡。

关键词：冠心病血管成形术支架置入术 PTCA 介入疗法

血脂相关性心血管剩留风险控制的中国专家共识

在线全文

学校读者我要写书评

暂无评论

中华心血管病杂志 2012年第7期40卷 547-553页

作者：无胡大一陆国平中华医学会心血管病学分会中国老年学学会心脑血管病专业委员会不详

近60年来，对心血管疾病危险因素的综合控制取得了显著成效。然而，经目前标准治疗，低密度脂蛋白胆固醇（LDL-C）、血压、血糖等传统危险因素得到控制后，血脂异常患者仍存在较高的心血管事件的剩留风险。致动脉粥样硬化性血脂异常，... 详细信息

近60年来，对心血管疾病危险因素的综合控制取得了显著成效。然而，经目前标准治疗，低密度脂蛋白胆固醇（LDL-C）、血压、血糖等传统危险因素得到控制后，血脂异常患者仍存在较高的心血管事件的剩留风险。致动脉粥样硬化性血脂异常，特别是升高的甘油三酯（TG）和较低的高密度脂蛋白胆固醇（HDL—C）在心血管病、2型糖尿病、代谢综合征或肥胖患者中很常见，与患者大血管事件和微血管事件的剩留风险相关。因此，在控制传统危险因素的同时，对心血管剩留风险进行干预和管理，有望进一步降低心血管事件。

关键词：心血管事件风险控制血脂异常相关性疾病危险因素低密度脂蛋白胆固醇高密度脂蛋白胆固醇动脉粥样硬化性

Evidence-based expert consensus on clinical management of safety of Bruton’s tyrosine kinase inhibitors(2024)

在线全文

学校读者我要写书评

暂无评论

chinese Journal of Cancer Research 2024年第3期36卷 240-256页

作者： Zaiwei Song Dan Jiang Lingling Yu Yixuan Chen Daobin Zhou Yue Li Depei Wu Lingli Zhang Liyan Miao Jun Ma Jun Zhu Hongmei Jing Rongsheng Zhao the Steering Committee,the Consensus Panel and the Evidence Synthesis Group Evidence-based Pharmacy Professional Committee of chinese Pharmaceutical association(CPA) Hospital Pharmacy Professional Committee of chinese Pharmaceutical association(CPA) Division of Therapeutic Drug Monitoring of chinese Pharmacological society(CPS) Expert Committee on Lymphoma of chinese society of Clinical Oncology(CSCO) Expert Committee on Leukemia of chinese society of Clinical Oncology(CSCO) society of Integrative Cardio-Oncology of China Anti-Cancer association(CACA) chinese society of Hematology of chinese medical association(CMA) Hospital Pharmacy Professional Committee of Cross-Straits Medicine Exchange association(SMEA) Department of Pharmacy Peking University Third HospitalBeijing 100191China Institute for Drug Evaluation Peking University Health Science CenterBeijing 100191China Therapeutic Drug Monitoring and Clinical Toxicology Center Peking UniversityBeijing 100191China Department of Pharmacy Administration and Clinical Pharmacy School of Pharmaceutical SciencesPeking UniversityBeijing 100191China Department of Hematology Peking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100005China Department of cardiology the First Affiliated HospitalHarbin Medical UniversityHarbin 150001China Department of Hematology the First Affiliated Hospital of Soochow UniversitySuzhou 215006China Department of Pharmacy Evidence-based Pharmacy CenterWest China Second HospitalSichuan UniversityChengdu 610041China Department of Pharmacy the First Affiliated Hospital of Soochow UniversitySuzhou 215006China Department of Hematology and Oncology Harbin Institute of Hematology and OncologyHarbin 150010China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of LymphomaPeking University Cancer Hospital&InstituteBeijing 100142China Department of Hematology Peking University Third HospitalBeijing 100191China 不详

Bruton’s tyrosine kinase inhibitors(BTKis)have revolutionized the treatment of B-cell ***,safety issues related to the use of BTKis may hinder treatment continuity and further affect clinical efficacy.A comprehensive and systematic expert consensus from a pharmacological perspective is lacking for safety issues associated with BTKi treatment.A multidisciplinary consensus working group was established,comprising 35 members from the fields of hematology,cardiovascular disease,cardio-oncology,clinical pharmacy,and evidencebased *** evidence-based expert consensus was formulated using an evidence-based approach and the Delphi *** Joanna Briggs Institute Critical Appraisal(JBI)tool and Grading of Recommendations Assessment,Development,and Evaluation(GRADE)approach were used to rate the quality of evidence and grade the strength of recommendations,*** consensus provides practical recommendations for BTKis medication based on nine aspects within three domains,including the management of common adverse drug events such as bleeding,cardiovascular events,and hematological toxicity,as well as the management of drug-drug interactions and guidance for special *** multidisciplinary expert consensus could contribute to promoting a multi-dimensional,comprehensive and standardized management of BTKis.

关键词： Consensus BTK inhibitors safety adverse drug events drug-drug interactions

在线全文

学校读者我要写书评

暂无评论

单片复方制剂降压治疗中国专家共识

中华高血压杂志 2019年第4期27卷 310-317页

作者：陈鲁原卢新政 <单片复方制剂降压治疗中国专家共识>专家组中华医学会心血管病学分会高血压学组

近十年来,与单药治疗或传统的阶梯治疗、序贯治疗等相比,两种或以上降压药物组成的单片复方制剂(SPC)可更有效地控制血压,并获国内外高血压指南的肯定和建议。2012年中华医学会心血管病学分会曾组织了有关SPC降压治疗的学术讨论,并发表... 详细信息

近十年来,与单药治疗或传统的阶梯治疗、序贯治疗等相比,两种或以上降压药物组成的单片复方制剂(SPC)可更有效地控制血压,并获国内外高血压指南的肯定和建议。2012年中华医学会心血管病学分会曾组织了有关SPC降压治疗的学术讨论,并发表了"单片复方制剂降压治疗中国专家共识"。数年过去,我国现阶段高血压的控制率仍然较低,SPC在降压药中的使用比例不高。不少降压达标率显著提升的成功经验显示,增加SPC使用率是提高血压达标率的主要途径之一。根据近年来国内外使用SPC的进展,中华医学会心血管病学分会组织有关专家对本共识文件进行修订,提出了SPC治疗流程建议,希望通过增加SPC的使用率提高我国降压达标率及高血压管理质量。

关键词：单片复方制剂高血压降压治疗共识

chinese national clinical practice guidelines on the prevention,diagnosis,and treatment of early gastric cancer

在线全文

学校读者我要写书评

暂无评论

chinese medical Journal 2024年第8期137卷 887-908页

作者： Peng Li Ziyu Li Enqiang Linghu Jiafu Ji society of Digestive Endoscopy of the chinese medical association Colorectal Surgery Group of the chinese medical association chinese association of Gastroenterologists&Hepatologists National Clinical Research Center for Digestive Diseases chinese medical Journal Clinical Practice Guideline Collaborative Department of Gastroenterology Beijing Friendship HospitalCapital Medical UniversityNational Clinical Research Center for Digestive DiseaseBeijing 100050China Department of Gastrointestinal Surgery Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Peking University Cancer Hospital and InstituteBeijing 100142China Department of Gastroenterology and Hepatology the First Medical CenterChinese People’s Liberation Army General HospitalBeijing 100853China 不详

Background:Gastric cancer is one of the most common malignant tumors in the digestive system in *** comprehensive practice guidelines for early gastric cancer in China are currently ***,we created the chinese national clinical practice guideline for the prevention,diagnosis,and treatment of early gastric ***:This clinical practice guideline(CPG)was developed in accordance with the World Health Organization’s recommended process and with the Grading of Recommendations Assessment,Development,and Evaluation(GRADE)in assessing evidence *** used the Evidence to Decision framework to formulate clinical recommendations to minimize bias and increase transparency in the CPG development *** used the Reporting Items for practice Guidelines in HealThcare(RIGHT)statement and the Appraisal of Guidelines for Research and Evaluation II(AGREE II)as reporting and conduct guidelines to ensure completeness and transparency of the ***:This CPG contains 40 recommendations regarding the prevention,screening,diagnosis,treatment,and follow-up of early gastric cancer based on available clinical studies and *** provide recommendations for the timing of Helicobacter pylori eradication,screening populations for early gastric cancer,indications for endoscopic resection and surgical gastrectomy,follow-up interval after treatment,and other ***:This CPG can lead to optimum care for patients and populations by providing up-to-date medical *** intend this CPG for widespread adoption to increase the standard of prevention,screening,diagnosis,treatment,and follow-up of early gastric cancer;thereby,contributing to improving national health care and patient quality of life.

关键词： Early gastric cancer Prevention Screening Diagnosis Treatment Follow-up

2023 chinese national clinical practice guideline on diagnosis and management of ulcerative colitis

在线全文

学校读者我要写书评

暂无评论

中华医学杂志(英文版) 2024年第14期137卷 1642-1646页

作者： Inflammatory Bowel Disease Group, chinese society of Gastroenterology, chinese medical association Inflammatory Bowel Disease Quality Control Center of China Inflammatory Bowel Disease Group Chinese Society of Gastroenterology Chinese Medical Association Inflammatory Bowel Disease Quality Control Center of China

The role of chinese expert consensus in standardization and improvement of the clinical diagnosis and treatment of inflammatory bowel disease (IBD) is self-evident. As clinical and basic research in China becomes standardized under a better understanding of IBD, more data on chinese patients have become available to develop a consensus and guideline. This guideline, collaboratively developed by the IBD Group, chinese society of Gastroenterology, incorporates the latest international consensus statements, domestic research findings, and practical considerations, as an update based on the 2018 chinese consensus on IBD management. The IBD guideline consists of two parts: ulcerative colitis (UC) and Crohn's disease, and this manuscript presented the UC part. The evidence used in this guideline was collected and analyzed by the standard of guideline, and the contents were organized as problem statements, for clarity. The formulation of this guideline aimed to reflect the latest progress in IBD, providing comprehensive and valuable guidance for the clinical management of IBD.

关键词：

同方期刊数据库

chinese national clinical practice guidelines on prevention,diagnosis and treatment of early colorectal cancer

在线全文

学校读者我要写书评

暂无评论

chinese medical Journal 2024年第17期137卷 2017-2039页

作者： Jingnan Li Hongwei Yao Yun Lu Shutian Zhang Zhongtao Zhang society of Digestive Endoscopy of the chinese medical association Colorectal Surgery Group of the chinese medical association chinese association of Gastroenterologist&Hepatologist National Clinical Research Center for Digestive Diseases chinese medical Journal Clinical Practie Guideline Collaborative Department of Gastroenterology Peking Union Medical College HospitalChinese Academy of Medical SciencesPeking Union Medical CollegeBeijing 100730China Department of General Surgery Beijing Friendship HospitalCapital Medical UniversityNational Clinical Research Center for Digestive DiseasesBeijing 100050China Department of General Surgery The Affiliated Hospital of Qingdao UniversityQingdaoShandong 266555China Department of Gastroenterology Beijing Friendship HospitalCapital Medical UniversityNational Clinical Research Center for Digestive DiseaseBeijing 100050China 不详

Background:The incidence and mortality of colorectal cancer(CRC)in China are increasing in recent *** clarified pathogenesis and detectable precancerous lesions of CRC make it possible to prevent,screen,and diagnose CRC at an early *** the development of endoscopic and surgical techniques,the choice of treatment for early CRC is also worth further discussion,and accordingly,a standard follow-up program after treatment needs to be ***:This clinical practice guideline(CPG)was developed following the recommended process of the World Health Organization,adopting Grading of Recommendations Assessment,Development and Evaluation(GRADE)in assessing evidence quality,and using the Evidence to Decision framework to formulate clinical recommendations,thereby minimizing bias and increasing transparency of the CPG development *** used the Reporting Items for practice Guidelines in HealThcare(RIGHT)statement and Appraisal of Guidelines for Research and Evaluation II(AGREE II)as reporting and conduct guides to ensure the guideline’s completeness and ***:This CPG comprises 46 recommendations concerning prevention,screening,diagnosis,treatment,and surveillance of *** these recommendations,we have indicated protective and risk factors for CRC and made recommendations for *** proposed a suitable screening program for CRC based on the chinese *** also provided normative statements for the diagnosis,treatment,and surveillance of CRC based on existing clinical evidence and ***:The 46 recommendations in this CPG are formed with consideration for stakeholders’values and preferences,feasibility,and *** are generalizable to resource-limited settings with similar CRC epidemiology pattern as China.

关键词： Colorectal cancer Early detection of cancer Prevention Screening Diagnosis Treatment Follow-up Guideline

在线全文

学校读者我要写书评

暂无评论

小儿心力衰竭诊断与治疗建议

中华儿科杂志 2006年第10期44卷 753-757页

作者：陈树宝李万镇马沛然钱永如宁寿葆中华医学会儿科学分会心血管学组 <中华儿科杂志>编辑委员会

心力衰竭（简称心衰）是小儿常见急症，如不及时治疗，可危及生命。近年来心脏器械检查与实验技术的发展较快，心衰已由定性诊断向半定量诊断发展。由于对心衰发病机理、病理生理的研究逐步深入，治疗方法也有很大进展。

关键词：半定量诊断治疗方法心力衰竭小儿心脏器械检查实验技术定性诊断发病机理

在线全文

学校读者我要写书评

暂无评论

甘油三酯增高的血脂异常防治中国专家共识

中华心血管病杂志 2011年第9期39卷 793-796页

作者：胡大一郭艺芳中国老年学学会心脑血管病专业委员会中华医学会心血管病学分会循证医学评论专家组

血脂异常是心血管系统最重要的危险因素之一。大量临床研究证实,应用他汀类药物降低胆固醇水平可以降低动脉粥样硬化性心血管疾病的发生率与致死致残率。然而近年研究显示,血脂异常患者即使经过大剂量他汀强化降胆固醇治疗后仍面临很高... 详细信息

血脂异常是心血管系统最重要的危险因素之一。大量临床研究证实,应用他汀类药物降低胆固醇水平可以降低动脉粥样硬化性心血管疾病的发生率与致死致残率。然而近年研究显示,血脂异常患者即使经过大剂量他汀强化降胆固醇治疗后仍面临很高的心血管剩留风险,而在2型糖尿病、肥胖、代谢综合征和(或)心血管病患者中,甘油三酯(TG)升高和高密度脂蛋白胆固醇(HDL-C)降低是构成心血管剩留风险的主要血脂异常表型。因此,在关注高胆固醇

关键词：血脂异常患者高TG血症筛查